737 844
population-based central cancer registries. Ann Surg Oncol 2013;
20:1759–65.
[12]
Gray PJ, Fedewa SA, Shipley WU, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 2013;63:823–9.
[13]
Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Database: A powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683–90.[14]
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–9.
[15]
Sooriakumaran P, Nyberg T, Akre O, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: Observational study of mortality outcomes. BMJ 2014;348:g1502.
[16]
Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiother- apy, or androgen-deprivation therapy for localized prostate cancer. Cancer 2010;116:5226–34.[17] Sun F, Oyesanmi O, Fontanarosa J, Reston J, Guzzo T, Schoelles K.
Therapies for clinically localized prostate cancer: Update of a
2008 systematic review. Rockville, MD: Agency for Healthcare
Research and Quality (US); 2014.
[18]
Barbash GI, Friedman B, Glied SA, Steiner CA. Factors associated with adoption of robotic surgical technology in US hospitals and relation- ship to radical prostatectomy procedure volume. Ann Surg 2014; 259:1–6.
[19]
Chang SL, Kibel AS, Brooks JD, Chung BI. The impact of robotic surgery on the surgical management of prostate cancer in the USA. BJU Int 2015;115:926–36.[20]
Womble PR, Montie JE, Ye Z, et al. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 2015;67:44–50.[21]
Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol 2013;190:1742–9.[22]
Shah C, L anni Jr TB, Ghilezan MI, et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy 2012;11:441–5.
[23]
Compton JJ, Gaspar LE, Shrieve DC, et al. Resident-reported brachy- therapy experience in ACGME-accredited radiation oncology train- ing programs. Brachytherapy 2013;12:622–7.[24] Bogdanich W. At V.A. Hospital, a Rogue Cancer Unit. The New York
Times. 2009.
[25]
Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomized, phase 3 trial. Lancet 2011;378:2104–11.[26]
Lin CC, Gray PJ, Jemal A, Efstathiou JA. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst 2015;107, djv119.
[27]
Mason MD, Parulekar WR, Sydes MR, et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 2015;33: 2143–50.[28]
Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/ SFUO-3): an open randomized phase III trial. Lancet 2009;373: 301–8.[29]
Berglund A, Garmo H, Robinson D, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer 2012;48:75–84.[30]
Furlow B. US National Cancer Institute investigates PSA coding errors. Lancet Oncol 2015;16:614.E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 7 2 9 – 7 3 7
737